Literature DB >> 18848530

Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation.

Megumi Funakoshi-Tago1, Kenji Tago, Chiho Nishizawa, Kyoko Takahashi, Tadahiko Mashino, Susumu Iwata, Hideo Inoue, Yoshiko Sonoda, Tadashi Kasahara.   

Abstract

Aberrant activation of Jak/Stat signaling causes a number of hematopoietic disorders and oncogenesis, and therefore the effective inhibitors of the Jak/Stat signaling pathway may be therapeutically useful. TEL-Jak2 gene fusion, which has been identified in human leukemia, encodes a chimeric protein endowed with constitutive tyrosine kinase activity. Expression of TEL-Jak2 protects Ba/F3 cells from IL-3 withdrawal-induced apoptotic cell death and leads to IL-3-independent growth. However, its mechanisms remain to be only partially understood. Here, we first found that Licochalcone A, one of the flavonoids isolated from the root of Glycyrrhiza inflate, inhibited TEL-Jak2-mediated cell proliferation and survival in the absence of IL-3. Licochalcone A failed to inhibit the activity of TEL-Jak2, however, this induced apoptosis of TEL-Jak2-transformed cells with a much lower concentration in the absence of IL-3 than in the presence of IL-3. Interestingly, Licochalcone A significantly inhibited the phosphorylation and nuclear localization of Stat3, which is essential for TEL-Jak2-induced cell transformation. These data suggest that Licochalcone A is a specific inhibitor for Stat3 and would be employed for the treatment of various diseases caused by disorders of the Jak/Stat pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848530     DOI: 10.1016/j.bcp.2008.09.012

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.

Authors:  Sara M N Onnebo; Parisa Rasighaemi; Janani Kumar; Clifford Liongue; Alister C Ward
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  A chalcone derivative, 1m-6, exhibits atheroprotective effects by increasing cholesterol efflux and reducing inflammation-induced endothelial dysfunction.

Authors:  Liv Weichien Chen; Min-Chien Tsai; Ching-Yuh Chern; Tien-Ping Tsao; Feng-Yen Lin; Sy-Jou Chen; Pi-Fen Tsui; Yao-Wen Liu; Hsien-Jui Lu; Wan-Lin Wu; Wei-Shiang Lin; Chien-Sung Tsai; Chin-Sheng Lin
Journal:  Br J Pharmacol       Date:  2020-07-20       Impact factor: 8.739

Review 3.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

4.  The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Kazuya Sumi; Miyuki Abe; Eriko Aizu-Yokota; Tomoyuki Oshio; Yoshiko Sonoda; Tadashi Kasahara
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

5.  Licochalcone A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide (LPS)-Induced Parkinson's Disease Models.

Authors:  Bingxu Huang; Juxiong Liu; Chen Ju; Dongxue Yang; Guangxin Chen; Shiyao Xu; Yalong Zeng; Xuan Yan; Wei Wang; Dianfeng Liu; Shoupeng Fu
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

6.  Effect of licochalcone A on growth and properties of Streptococcus suis.

Authors:  Huaijie Hao; Wenjia Hui; Peng Liu; Qingyu Lv; Xiaotao Zeng; Hua Jiang; Yanzi Wang; Xin Zheng; Yuling Zheng; Jianchun Li; Xuyu Zhou; Yongqiang Jiang
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

7.  The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.

Authors:  Sophia Pinz; Samy Unser; Susanne Brueggemann; Elisabeth Besl; Nafisah Al-Rifai; Hermina Petkes; Sabine Amslinger; Anne Rascle
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

Review 8.  Integration of phytochemicals and phytotherapy into cancer precision medicine.

Authors:  Thomas Efferth; Mohamed E M Saeed; Elhaj Mirghani; Awadh Alim; Zahir Yassin; Elfatih Saeed; Hassan E Khalid; Salah Daak
Journal:  Oncotarget       Date:  2017-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.